Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $6.53 and last traded at $6.56, with a volume of 787378 shares changing hands. The stock had previously closed at $6.95.
Analyst Upgrades and Downgrades
VIR has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. Leerink Partners boosted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. HC Wainwright reiterated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. Barclays boosted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Vir Biotechnology has an average rating of "Moderate Buy" and an average price target of $35.67.
Get Our Latest Stock Analysis on VIR
Vir Biotechnology Trading Up 0.4 %
The firm's 50 day moving average price is $8.80 and its 200-day moving average price is $8.35. The company has a market cap of $918.86 million, a P/E ratio of -1.71 and a beta of 1.17.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, EVP Verneuil Vanina De sold 7,373 shares of Vir Biotechnology stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the sale, the executive vice president now owns 79,460 shares of the company's stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock valued at $326,458 in the last quarter. 15.60% of the stock is currently owned by insiders.
Institutional Trading of Vir Biotechnology
Several institutional investors and hedge funds have recently added to or reduced their stakes in VIR. Point72 Asia Singapore Pte. Ltd. bought a new position in Vir Biotechnology during the fourth quarter worth about $42,000. SBI Securities Co. Ltd. acquired a new position in shares of Vir Biotechnology during the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. raised its stake in Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after acquiring an additional 1,999 shares during the period. KBC Group NV lifted its holdings in Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after purchasing an additional 5,177 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in Vir Biotechnology during the fourth quarter worth $74,000. 65.32% of the stock is owned by institutional investors.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Further Reading
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
